AlphaMaven AlphaMaven
General Atlantic, Aquitaine, Avesi, PPC Enterprises target speech therapy; Stable pharmaceutical demand leads SK Capital-backed Apotex to C$1.3bn IPO
Back to News
AlphaMaven Alternative Investment News
Private Equity

General Atlantic, Aquitaine, Avesi, PPC Enterprises target speech therapy; Stable pharmaceutical demand leads SK Capital-backed Apotex to C$1.3bn IPO

pehub
3 months ago
Early intervention is leading to more diagnoses in children of conditions that require speech therapy, fueling demand in the segment and catching the eye of private equity; discussing the largest life sciences IPO in the Toronto Stock Exchange’s history, launched by SK Capital-backed Apotex.
The post General Atlantic, Aquitaine, Avesi, PPC Enterprises target speech therapy; Stable pharmaceutical demand leads SK Capital-backed Apotex to C$1.3bn IPO appeared first on PE Hub.

Read the full intelligence on AlphaMaven

Subscribe to unlock the AI-extracted Key Takeaways, the News Summary that synthesizes this story with related coverage, and the full alternative-investment intelligence platform — $99/mo, no contract, cancel anytime.

Start research — $99/mo Login

News Summary available

Subscribe to unlock the News Summary

Key Takeaways + full Summary on every story · $99/mo, no contract

Start research — $99/mo

Not a member yet?

Why AlphaMaven

The Alternative Investment
Intelligence Platform

Access nearly 1 million industry profiles in alternative investments — firms, funds, decision-makers and regulatory filings.

Start a free 7-day trial — card required, cancel anytime
Data · Intelligence · ROI
Company, fund & contact directory
Screener with filters & saved searches
Regulatory data — SEC, NFA, GLEIF, Form D
Manager-reported fund performance
11K+ members contributing data
Daily news with AI executive summaries
Data exports from your tracked list
Research guides, leaderboards & glossary
59,200+
Firms
365,700+
Decision-Makers
70,000+
Data Sources
Start your free 7-day trial

ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.

© 2026 Maven Data Group, Inc.